AMED icon

Amedisys

90.44 USD
-0.65
0.71%
At close Feb 21, 4:00 PM EST
After hours
90.44
+0.00
0.00%
1 day
-0.71%
5 days
-2.52%
1 month
-1.89%
3 months
0.31%
6 months
-7.61%
Year to date
-0.51%
1 year
-3.39%
5 years
-53.39%
10 years
210.04%
 

About: Amedisys Inc is a healthcare services company in the United States. The company brings healthcare to the home through the provision of home healthcare services, hospice services, high acuity care segment, and personal care services. The Home Health Segment provides skilled nurses, therapists, and aids to patients' homes throughout the United States, Hospice segment operates many centers designed to provide comfort and support for terminally ill patients, Personal Care Segment provides individuals with assistance in their daily living activities and High acuity care segment can deliver the essential elements of inpatient hospital, SNF care, and palliative care to patients in their homes. A majority of the company's revenue is derived from the Home Health segment.

Employees: 19,000

0
Funds holding %
of 7,139 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

23% more first-time investments, than exits

New positions opened: 53 | Existing positions closed: 43

20% more repeat investments, than reductions

Existing positions increased: 98 | Existing positions reduced: 82

4.59% more ownership

Funds ownership: 86.76% [Q3] → 91.35% (+4.59%) [Q4]

2% more funds holding

Funds holding: 275 [Q3] → 281 (+6) [Q4]

3% less capital invested

Capital invested by funds: $2.74B [Q3] → $2.67B (-$72.1M) [Q4]

25% less funds holding in top 10

Funds holding in top 10: 12 [Q3] → 9 (-3) [Q4]

79% less call options, than puts

Call options by funds: $71M | Put options by funds: $342M

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$101
12%
upside
Avg. target
$101
12%
upside
High target
$101
12%
upside

1 analyst rating

positive
0%
neutral
100%
negative
0%
Stephens & Co.
Raj Kumar
33% 1-year accuracy
1 / 3 met price target
12%upside
$101
Equal-Weight
Reiterated
12 Feb 2025

Financial journalist opinion

Based on 3 articles about AMED published over the past 30 days

Neutral
Zacks Investment Research
1 week ago
Amedisys (AMED) Earnings Expected to Grow: Should You Buy?
Amedisys (AMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amedisys (AMED) Earnings Expected to Grow: Should You Buy?
Neutral
GlobeNewsWire
2 weeks ago
Amedisys Honors 47 Employees With Annual Spirit of Excellence Award
BATON ROUGE, La., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice and high-acuity care services, has recognized 47 employees with the prestigious Spirit of Excellence Awards, one of the company's highest honors.
Amedisys Honors 47 Employees With Annual Spirit of Excellence Award
Positive
MarketBeat
3 weeks ago
3 Stocks to Gain From Trump's Family Caregiver Tax Credits
President Trump has endorsed the passage of a tax credit for family caregivers. The tax credit would be given to caregivers who take care of a parent, family member, or a loved one.
3 Stocks to Gain From Trump's Family Caregiver Tax Credits
Negative
Zacks Investment Research
1 month ago
UnitedHealth's $3.3B Merger Stalls as VitalCaring Sale Falls Through
UNH and AMED are now expected to identify new buyers for the divestment assets by March 2025.
UnitedHealth's $3.3B Merger Stalls as VitalCaring Sale Falls Through
Negative
Zacks Investment Research
1 month ago
Reasons to Retain AMED Stock in Your Portfolio Now
Amedisys' expected merger with UnitedHealth Group's Optum brings optimism to investors. Yet, a dull macroeconomic condition adds to the worry.
Reasons to Retain AMED Stock in Your Portfolio Now
Neutral
Proactive Investors
1 month ago
UnitedHealth and Amedisys extend $3.3B merger deadline amid DOJ scrutiny
UnitedHealth Group Inc (NYSE:UNH, ETR:UNH) and Amedisys (NASDAQ:AMED) have agreed to extend the deadline for their $3.3 billion merger, facing ongoing scrutiny from the US Department of Justice (DOJ). The companies announced in a regulatory filing that the merger deadline will now be extended to 10 days after a final court decision is issued or December 31, 2025, whichever comes first.
UnitedHealth and Amedisys extend $3.3B merger deadline amid DOJ scrutiny
Neutral
Investopedia
1 month ago
Amedisys, UnitedHealth Group Extend Deadline To Complete $3.3B Merger
UnitedHealth Group (UNH) and Amedisys (AMED) agreed to extend the deadline to complete their $3.3 billion merger, after the U.S. Department of Justice moved to block it.
Amedisys, UnitedHealth Group Extend Deadline To Complete $3.3B Merger
Positive
Benzinga
1 month ago
Amedisys and UnitedHealth Extend Merger Deadline - What's Going On?
Amedisys Inc AMED shares are trading higher on Friday after the company announced it extended its merger deadline with UnitedHealth Group Incorporated UNH.
Amedisys and UnitedHealth Extend Merger Deadline - What's Going On?
Neutral
Reuters
1 month ago
UnitedHealth, Amedisys extend deadline to close $3.3 billion deal
UnitedHealth and Amedisys have agreed to extend the deadline to close their $3.3 billion merger agreement to next year, a filing showed on Friday, as the deal faces close scrutiny from the U.S. Department of Justice.
UnitedHealth, Amedisys extend deadline to close $3.3 billion deal
Negative
Zacks Investment Research
3 months ago
DOJ Lawsuit Questions UnitedHealth's $3.3 Billion Amedisys Deal
The DOJ suggests that UNH's acquisitions reflect a strategy of buying competitors rather than competing directly, potentially giving it control over multiple markets.
DOJ Lawsuit Questions UnitedHealth's $3.3 Billion Amedisys Deal
Charts implemented using Lightweight Charts™